Evidence map›Paper›PMID 41027327›Full record

ArticlePublic health2025

Diabetes incidence before and after the pandemic onset in adult subgroups with prediabetes.

Luis A Rodriguez, Maher Yassin, O Kenrik Duru, Romain S Neugebauer, Brandon Towns, Tainayah W Thomas, Susan D Brown, Yelba Castellon-Lopez, Julie A Schmittdiel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luis A RodriguezKaiser Permanente Northern California, Division of Research, Pleasanton, CA, USA; Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health Systems Science, Pasadena, CA, USA; University of California, San Francisco, Department of Epidemiology & Biostatistics, San Francisco, CA, USA. Electronic address: Luis.A.Rodriguez@kp.org.
Maher YassinKaiser Permanente Northern California, Division of Research, Pleasanton, CA, USA.
O Kenrik DuruUniversity of California, Los Angeles, Department of Medicine, Los Angeles, CA, USA.
Romain S NeugebauerKaiser Permanente Northern California, Division of Research, Pleasanton, CA, USA.
Brandon TownsKaiser Permanente Bernard J. Tyson School of Medicine, Department of Health Systems Science, Pasadena, CA, USA.
Tainayah W ThomasStanford University, Department of Epidemiology and Population Health, Stanford, CA, USA.
Susan D BrownUniversity of California, Davis, Department of Internal Medicine, Sacramento, CA, USA.
Yelba Castellon-LopezCedars-Sinai Cancer Research Center for Health Equity, Los Angeles, CA, USA.
Julie A SchmittdielKaiser Permanente Northern California, Division of Research, Pleasanton, CA, USA; Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health Systems Science, Pasadena, CA, USA.

Funding

Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Alyce Sophia Adams, HILARY Kessler SELIGMAN · 2011 to 2026
$9.2M
A Multi-Level Evaluation of California's New Medicaid Coverage for the Diabetes Prevention ProgramR18DK122372 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DURU, OBIDIUGWU KENRIK · 2020 to 2024
$3.2M
Empirically Based Career Development Program for Historically Under-Represented Early Career Trainees Supported by NIDDKUE5DK137286 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elena Flowers · 2023 to 2026
$635k
Evaluating Biologic and Sociodemographic Factors to Improve Diabetes Prevention in AdultsK01DK138122 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Luis A Rodriguez · 2024 to 2026
$471k
NIDDK NIH HHS K01 DK138122NIDDK NIH HHS P30 DK092924NIDDK NIH HHS R18 DK122372NIDDK NIH HHS UE5 DK137286
6 · The paper itself

Abstract

objectivesDuring the COVID-19 pandemic, type 2 diabetes (T2D) incidence increased, but it remains unclear if different groups were disproportionately affected. We evaluated overall changes in T2D incidence before and during the pandemic and by insurance type, sex, and race/ethnicity subgroups. STUDY

designRetrospective dynamic cohort.

methodsWe included 323,609 adults (≥18-89 years) with prediabetes and BMI ≥25 kg/m

resultsBefore the pandemic, monthly T2D incidence was stable. After the pandemic onset, the monthly trend increased by 6.5 % (-0.2 %, 10.3 %) for comprehensive and 3.2 % (0.6 %, 5.1 %) for lab-only; both trends persisted through 2021. After accounting for differential screening bias this increase remained but was not significant given wider confidence intervals. T2D incidence level for lab-only increased 51 % more among Hispanic vs. White adults and persisted through 2021. No other group differences were observed.

conclusionsThe pandemic onset was followed by an increase in T2D incidence overall and with sharper increases among Hispanic adults. This highlights the broader health changes of the pandemic and underscores the need for public health strategies to manage this growing burden.

Indexed as

COVID-19Diabetes Mellitus, Type 2Prediabetic StateAdolescentAdultAgedAged, 80 and overCaliforniaFemaleHumansIncidenceMaleMiddle AgedPandemicsRetrospective StudiesSARS-CoV-2Adults with prediabetesCOVID-19 pandemicInterrupted time seriesType 2 diabetes incidence

Identifiers

PMID41027327
PMCPMC12512140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.